Name | ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate |
Synonyms | Noopept GVS 111 SGS 111 GVS-111 noopept powder Nootropic GVS-111 ethyl phenylacetyl-Pro-Gly Ethyl 1-(phenylacetyl)-L-prolylglycinate ethyl 1-(phenylacetyl)-L-prolylglycinate N-(1-(Phenylacetyl)-L-prolyl)glycineethylester N-(1-(Phenylacetyl)-L-prolyl)glycine ethyl ester Glycine, 1-(phenylacetyl)-L-prolyl-, ethyl ester Glycine, N-(1-(phenylacetyl)-L-prolyl)-, ethyl ester (S)-ethyl 2-(1-(2-phenylacetyl)pyrrolidine-2-carboxaMido)acetate ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate |
CAS | 157115-85-0 |
EINECS | 1592732-453-0 |
InChI | InChI=1/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1 |
Molecular Formula | C17H22N2O4 |
Molar Mass | 318.37 |
Density | 1.202±0.06 g/cm3(Predicted) |
Melting Point | 94.0 to 98.0 °C |
Boling Point | 547.3±50.0 °C(Predicted) |
Flash Point | 284.8°C |
Solubility | Soluble in DMSO (up to 25 mg/ml) |
Vapor Presure | 4.93E-12mmHg at 25°C |
Appearance | powder |
Color | white to beige |
pKa | 13.41±0.20(Predicted) |
Storage Condition | -20°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months. |
Refractive Index | 1.548 |
In vitro study | Nooglutil exhibits pharmacologically significant competition with a selective agonist of AMPA receptors ([G-3H]Ro 48-8587) for the receptor binding sites (with IC50 = 6.4 +/- 0.2 microM), while the competition of noopept for these receptor binding sites was lower by an order of magnitude (IC50 = 80 +/- 5.6 microM) [1]. GVS-111 significantly increased neuronal survival after H(2)O(2)-treatment displaying a dose-dependent neuroprotective activity from 10 nM to 100 microM, and an IC(50) value of 1.21+/-0.07 microM. GVS-111 inhibited the accumulation of intracellular free radicals and lipid peroxidation damage in neurons treated with H(2)O(2) or FeSO(4), suggesting an antioxidant mechanism of action [2]. |
In vivo study | N-Phenylacetyl-L-prolylglycine ethyl ester (GVS-111) administered intravenously at a dose of 0.5 mg/kg/day, for the first time 1 h after ischaemic lesion and then for 9 post-operative days, with the last administration 15 min before testing, attenuated the deficit [3]. GVS-111 itself was not found in rat brain 1 h after 5 mg/kg i.p. administration up to limit of detection (LOD) under high performance liquid chromatography (HPLC) conditions [4]. The most pronounced antiinflammatory effect of dipeptide was observed on the model of adjuvant arthritis in rats, where the drug administered over 25 days in a daily dose of 0.5 mg/kg (i.m.) or 5 mg/kg (p.o.) significantly reduced the chronic immune inflammation (on the 12th day, by 94.0 and 74.1%, respectively) [5]. |
RTECS | MC0814400 |
HS Code | 29339900 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.141 ml | 15.705 ml | 31.41 ml |
5 mM | 0.628 ml | 3.141 ml | 6.282 ml |
10 mM | 0.314 ml | 1.57 ml | 3.141 ml |
5 mM | 0.063 ml | 0.314 ml | 0.628 ml |
update date: | 2022/11/12 10:05:38 |
Introduction | The trade name of N-(1-(phenylacetyl)-L-prolyl) glycine ethyl ester is NOOPEPT for the treatment of obesity, alcohol dependence Degeneration or toxic damage and other diseases. |
biological activity | Omberacetam (GVS-111) is a polypeptide that can be used as a dietary supplement. |